Bayer picks up off-the-shelf CAR-T approach from Atara, spotlighting a Memorial Sloan Kettering breakthrough
Bayer’s brand new cell & gene therapy strategy now also features CAR-T.
In a new deal with Atara Biotherapeutics, the German pharma has reserved $610 million — $60 million of that upfront — to spend on two cell therapies directed at mesothelin. ATA3271, an off-the-shelf therapy, is the main focus but an autologous version of it is also part of the pact.
The goal? To go after high mesothelin-expressing solid tumors such as malignant pleural mesothelioma and non-small-cell lung cancer.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,200+ biopharma pros reading Endpoints daily — and it's free.